The presence of tumor-specific activated stromal cells in our data suggest the applicability of cell type depletion strategies that are currently under development such as LRRC15 [78] and CCR8 [79] antibody drug conjugates in gastric cancer. This evidence concerns the gene LRRC15 and neoplasm.